Alcami Announces Manufacturing Agreement for Solasia's Active Pharmaceutical Ingredient Darinaparsin

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Friday, November 10th, 2017

DURHAM, North Carolina, Nov. 9, 2017 /PRNewswire/ Korea IT times-- Alcami, a leading provider of custom end-to-end development and manufacturing services for the pharmaceutical and biotechnology industries, today announces it has finalized manufacturing and quality agreements with Solasia Pharma, K.K. (TSE: 4597) for the clinical supply manufacture of the active pharmaceutical ingredient (API) darinaparsin, a novel mitochondrial-targeted agent developed for the treatment of various hematologic and solid cancers.

Solasia is a Japan-based specialty pharmaceutical company dedicated to the development of innovative oncology medicines. In March 2011, Solasia acquired the rights to darinaparsin from ZIOPHARM Oncology, Inc. for the potential treatment of Peripheral T-Cell Lymphoma (PTCL). The agent is currently in Phase II pivotal trials in Asia.

"We are pleased to entrust Alcami with this project," said Mr. Yoshihiro Arai, President and CEO of Solasia Pharma, K.K. "Finding a responsible partner for the development and manufacturing of our API was a significant step in our clinical program."

Process development for darinaparsin and clinical manufacturing will begin within Alcami's new highly potent API suites in Q4 2017, located at its API Center of Excellence facility in Germantown, Wisconsin.    

"We are extremely grateful for the opportunity to partner with Solasia as the trusted supplier of darinaparsin. Our relationship is an excellent example of Alcami's dedication to delivering reliable and high quality medicines across the globe. As we continue to grow our established business in Japan, we look forward to supporting Solasia for its future clinical and commercial success," stated Syed T. Husain, Chief Commercial Officer of Alcami.

ABOUT SOLASIA
Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers. Additional information is available at solasia.co.jp/en/.

ABOUT ALCAMI
Alcami is a world-class contract development and manufacturing organization (CDMO) headquartered in North Carolina, with executive offices in Durham and Wilmington. With over 1,000 employees operating at eight global locations, Alcami provides customizable and innovative end-to-end services to small and mid-size pharmaceutical and biotechnology companies by offering individualized and integrated services across multiple areas. We connect our clients with innovative solutions for API development and manufacturing, solid-state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid dose and parenteral), packaging, and stability services. For more information, please visit alcaminow.com.

Logo - https://mma.prnewswire.com/media/600436/Alcami_Logo.jpg

Comments

samsung fire

new energy